

Information for Connecticut Prescribers of Prescription Drugs

ABRILADA™ (adalimumab-afzb) injection, for subcutaneous use

The prices listed below are Wholesale Acquisition Costs (“WAC”) established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about the WAC of this drug is being provided to Connecticut prescribers pursuant to Connecticut law, to give prescribers information about the WAC price of marketed drugs.

Marketed Product*:	WAC Package	Package Size
ABRILADA(CF) PEN 40 MG/0.8 ML	\$1,384.52	1
ABRILADA(CF) PEN 40 MG/0.8 ML	\$2,769.04	1
ABRILADA(CF) PEN 40 MG/0.8 ML	\$3,288.25	1
ABRILADA(CF) PEN 40 MG/0.8 ML	\$6,576.49	1
ABRILADA(CF) 40 MG/0.8 ML SYRINGE	\$2,769.04	2
ABRILADA(CF) 20 MG/0.4 ML SYRINGE	\$2,769.04	2
ABRILADA(CF) 40 MG/0.8 ML SYRINGE	\$6,576.49	2
ABRILADA(CF) 20 MG/0.4 ML SYRINGE	\$6,576.49	2

*Prices shown are for the lowest dosage of the product.

This information is being provided pursuant to CT House Bill 6669. The information is accurate as of July 09, 2024. The prices listed are WAC prices, which represent Pfizer’s published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction. The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product’s WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed.

Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made. For additional drug and price information see: <http://www.pfizer.com/ctprescribers>

Data as of: 09-Jul-2024